For research use only. Not for therapeutic Use.
Tezacaftor-d4 (CAS: 1961280-24-9), a premium pharmaceutical research compound designed for advanced cystic fibrosis studies. As a deuterated analog of Tezacaftor, it offers enhanced stability and improved pharmacokinetic properties. Tezacaftor-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for cystic fibrosis and related conditions. Trusted by leading laboratories, Tezacaftor-d4 is your go-to solution for cutting-edge cystic fibrosis research. Unlock new possibilities in cystic fibrosis treatment with Tezacaftor-d4, where innovation meets reliability.
| Catalog Number | S000207 |
| CAS Number | 1961280-24-9 |
| Molecular Formula | C26H23D4F3N2O6 |
| Purity | ≥95% |
| Target | Autophagy |
| IUPAC Name | 2,2,3,3-tetradeuterio-1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide |
| InChI | InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1/i5D2,6D2 |
| InChIKey | MJUVRTYWUMPBTR-YKSUQDSQSA-N |
| SMILES | [2H]C1(C(C1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=C5C(=C4)C=C(N5C[C@H](CO)O)C(C)(C)CO)F)([2H])[2H])[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. April 18, 2013 [3]. Taylor-Cousar JL, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 Nov 23;377(21):2013-2023. [4]. Burgel PR, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. |
